The overall conclusion is that hNGFp delivered intranasally can ameliorate symptoms in the MeCP2+/− model of Rett syndrome, by exerting strong neuroprotection with a dual mechanism of action: directly on target neurons and indirectly via microglia. This evidence concerns the gene MECP2 and atypical Rett syndrome.